 |
 |
|
The widespread availability of antibiotics beginning in the 1940s revolutionized medical care. Today, however, many bacterial infections are developing resistance to the most commonly prescribed antibiotic treatments, and the incidence of "superbugs" is on the rise. |
Our world's health is at risk. Deadly diseases, once though conquered, have reemerged in drug-resistant forms. Globalization — from air travel to food production — has opened new doors for bacteria and viruses to enter the U.S. One of CDC's most visible roles is identifying and controlling outbreaks of infectious diseases and protecting us from emerging infectious threats. The CDC Foundation provides opportunities for organizations in the private sector to support CDC's efforts and join in the fight. Examples of CDC Foundation partnerships that are improving CDC's ability to fight infectious diseases are listed below.
Featured Program:
|
Infectious Disease Programs
- Capsule-based Reverse Vaccinology for N. meningitides
- Chronic Viral Hepatitis B and C Cohort Study
- Control of Cytomegalovirus (CMV) by Cell-Type-Specific Neutralizing Antibodies
- Cytomegalovirus (CMV) Seroprevalence Study
- Development of a Mucosal Subunit TB Vaccine
- District of Columbia Immunization Registry
- Foodborne Illness Prevention
- Get Smart: Know When Antibiotics Work
- Improving Safe Injection Practices
- Malaria Research and Reference Reagent Repository
- MRSA Surveillance
- Nasal Aerosol Delivery of Influenza VLP Vaccines
- National MRSA Education Initiative
- Neglected Burden of Human Vivax Malaria
- Nipah Virus Antivirals
- Organ Transplant Infection Prevention Project
- Prevent Antimicrobial Resistance in Healthcare Setting
- RSV Protective Antibodies in Young Children
- Schistosome Infection and HIV/AIDS
- Structural Studies of Hepatitis B Virus Surface Antigen
- Safe Care Campaign
- Tuberculosis Trials Consortium Study
- Understanding Immunological Responses to Vaccines
- Viral Hepatitis Action Coalition
 |
|
To conduct a series of genomic analyses of pathogenic N. meningitidis strains (bacteria that cause meningitis and sepsis) to improve the development and composition of N. meningitidis vaccines.Â
|
|
|
To establish the first comprehensive U.S. longitudinal observational cohort of 15,000 or more patients with chronic viral hepatitis B and C in order to improve understanding of chronic viral hepatitis and the impact of screening, care and treatment recommendations.
Related Information: |
|
|
To develop strategies to control cytomegalovirus (CMV) congenital infection, which affects as many as 10,000 children per year in the U.S.
|
|
|
To assess cytomegalovirus (CMV) seroprevalence in the current U.S. population and to identify time trends and risk factors for infection. CMV is the most common congenital (present at birth) infection in the United States.
|
|
|
To continue research on the best strategies to develop and deliver a needle-free intranasal mucosal vaccine against tuberculosis (TB).
|
|
|
To allow the District of Columbia Health Department to continue to manage the District's Immunization Registry to ensure the protection of susceptible individuals from preventable diseases.
|
|
|
To develop and test a needle-free nasal aerosol method for administering an influenza vaccine based on egg-free manufacturing of viruslike-particles (VLPs).
|
|
|
To help identify potential antiviral compounds effective against Nipah virus.
|
|
|
To develop a series of health communications aimed at increasing awareness among physicians of CDC’s goals of preventing the spread of antimicrobial resistance. The goal of this initiative is to develop an integrated program to prevent emergence and spread of antimicrobial-resistance infections among patients in healthcare settings.
|
|
|
To explore the possibility of developing a safe and effective vaccine for respiratory syncytial virus (RSV) - the single most important cause of serious lower respiratory tract infections in children less than 1 year old - by determining if maternally acquired anti-G protein antibodies that block binding to CX3CR1 contribute to protection from RSV.
|
|
|
To further define the mechanism(s) by which schistosome infection increases host susceptibility to immunodeficiency virus infections and help determine what public health interventions may be useful in areas highly endemic for both schistosomaisis and HIV/AIDS.
|
|
|
To increase understanding of the structure of hepatitis B virus (HBV) surface antigen (HBsAg) protein in order to develop improved HBV vaccines and bivalent vaccines.
|
|
|
To evaluate the safety and tolerability of the antibiotic linezolid in the treatment of multi-drug resistant and extensively drug resistant tuberculosis when added to optimized background therapy.
|
|
|
To improve understanding of the basic immunological mechansims that affect vaccine efficacy in order to facilitate the design of new, improved and novel bacterial vaccines.
|
|
|
The Viral Hepatitis Action Coalition, led by CDC and the CDC Foundation, is composed of private sector organizations and community partners committed to making meaningful advances in the prevention, screening and treatment of viral hepatitis. The Coalition provides an overall framework to respond to upcoming issues of importance in the field, guide a national education campaign and support CDC-led research and program evaluation. The Coalition will work with the CDC Foundation to help CDC form public-private partnerships to launch CDC-initiated projects.The Coalition's first priorities will be to increase awareness and to fund essential research to build the evidence needed to revise the national recommendations for hepatitis screening and testing.
Related Information: |